Martin Shkreli and Jim Tananbaum were selected in the LSIPR 50 2016 publication for their influence on the life sciences industry. Shkreli and Tananbaum were featured in the investment section, as LSIPR reports.
Name: Martin Shkreli
Organisation: Formerly of Turing Pharmaceuticals
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Martin Shkreli, Jim Tananbaum, Turing Pharmaceuticals, drugs, Foresite Capital, Jazz Pharmaceuticals,
